human ERBB2 protein

should not be indexed with MH=Receptor, Epidermal Growth Factor, RefSeq NM_001005862

Also Known As:

ERBB2 protein, human; EGFR2 protein, human; HER-2 protein, human; HER2 protein, human; HER2delta16 protein, human; Neu protein, human; epidermal growth factor receptor 2, human; human epidermal growth factor receptor 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 protein, human

Networked: 6137 relevant articles (345 outcomes, 724 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Im, Seock-Ah: 34 articles (10/2022 - 10/2008)
2.	Winer, Eric P: 34 articles (10/2022 - 01/2003)
3.	Hortobagyi, Gabriel N: 33 articles (10/2022 - 01/2004)
4.	Perez, Edith A: 31 articles (07/2022 - 01/2006)
5.	Baselga, José: 31 articles (01/2020 - 04/2005)
6.	de Azambuja, Evandro: 30 articles (07/2022 - 02/2006)
7.	Harbeck, Nadia: 28 articles (10/2022 - 12/2009)
8.	Viale, Giuseppe: 28 articles (01/2022 - 12/2005)
9.	Xu, Binghe: 27 articles (04/2022 - 09/2012)
10.	Wolff, Antonio C: 27 articles (01/2022 - 01/2007)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 11/01/2015 - "The development of human epidermal growth factor receptor 2 (HER2)-targeting agents for the treatment of HER2-amplified breast cancer has dramatically improved outcomes for patients with this disease. " 06/01/2023 - "Subgroup analysis revealed that elevated FOXP3+ TILs were significantly associated with improved pCR (OR: 1.20, 95% CI 1.02-1.40) and OS (HR: 0.22, 95% CI 0.06-0.88) in human epidermal growth factor receptor 2 positive (HER2+) breast cancer patients. " 12/01/2022 - "Treatment advances have improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (eBC) but certain patients remain at high risk of recurrence. " 03/15/2022 - "Despite significant survival improvement in human epidermal growth factor receptor 2 (HER2) blockade for HER2-positive breast cancer, resistance to anti-HER2 remains inevitable. " 07/18/2023 - "Several anti-human epidermal growth factor receptor 2 (HER2) treatments have improved the landscape of HER2-positive breast cancer (BC) over the past few years; due to the heterogeneity of the disease itself, the drug resistance mechanisms and relapse are still the main issue in HER2-positive BC. "
2.	Neoplasms (Cancer) 01/01/2018 - "Pharmaceutical inhibition of the Human Epidermal growth factor Receptor 2 (HER2) oncogene has dramatically improved outcomes in HER2-amplified breast cancers. " 05/30/2018 - "The advantages offered by this platform in terms of high sensitivity, broad dynamic range and low-cost demonstrates great potential for improved monitoring of human epidermal growth factor receptor 2 levels for the management of breast and other cancers." 09/01/2017 - "Younger patients with HR-positive and human epidermal growth factor receptor 2 (HER2)-negative tumor subtypes had a significantly improved DFS over time (p = 0.032). " 09/01/2019 - "Human epidermal growth factor receptor 2 (HER2)-targeted agents are effective against HER2-positive breast cancers. " 08/01/2022 - "Considering these results, the aptasensors demonstrate great potential for improved monitoring of human epidermal growth factor receptor 2 levels for the management of breast cancers."
3.	Stomach Neoplasms (Stomach Cancer) 01/01/2022 - "The aim of this study was to retrospectively evaluate the efficacy of full management from first-line to third-line treatments in patients with human epidermal growth factor receptor 2 (Her-2)-negative advanced gastric cancer (GC). " 06/01/2023 - "This study aimed to assess the correlation between CT-derived body composition parameters and SII and OS in patients with advanced gastric cancer receiving dual programmed death-1 (PD-1) and human epidermal growth factor receptor 2 (HER2) blockade. " 05/13/2022 - "Studies have confirmed the prognostic value of the expression status of human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer. " 01/01/2021 - "The objective of the study was to evaluate the human epidermal growth factor receptor 2 (HER2) overexpression, clinicopathological features, and factors affecting survival in patients with gastric cancer. " 01/01/2021 - "The purpose of this study was to develop and evaluate a dual-energy CT (DECT)-based nomogram for noninvasive identification of the status of human epidermal growth factor receptor 2 (HER2; also known as ERBB2) expression in gastric cancer (GC). "
4.	Adenocarcinoma 07/01/2022 - "Despite promising results following targeted treatment with human epidermal growth factor receptor 2 (HER2)-inhibitors in HER2-positive gastric and esophageal adenocarcinoma (GEA), prognosis remains dismal. " 01/01/2023 - "There is an urgent need for first-line treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. " 10/01/2023 - "A study of human epidermal growth factor receptor 2 overexpression by immunohistochemistry in patients with gastric adenocarcinoma." 08/01/2022 - "The study of the population included metastatic human epidermal growth factor receptor 2 (HER2) negative gastric adenocarcinoma with peritoneal involvement. " 06/30/2023 - "In this report, we present a case of a patient with a 30-year history of orbital asymmetry who presented with metastatic human epidermal growth factor receptor 2 (HER2) positive lacrimal/salivary gland ductal adenocarcinoma. "
5.	Neoplasm Metastasis (Metastasis) 10/20/2015 - "The present study provides direct evidence of the role of FOXO1 in tumour growth and metastasis of GC in relation to human epidermal growth factor receptor 2 (HER2). " 07/01/2014 - "To the best of our knowledge, the present study is the first to report IAC metastasis due to LMC in human epidermal growth factor receptor 2 (Her2)-positive GC. " 01/01/2023 - "Higher comorbidity burden, namely cardiometabolic conditions were associated with unfavourable pathological features including larger tumours, involvement of >9 axillary lymph nodes, distant metastasis and human epidermal growth factor receptor 2 overexpression. " 05/01/2022 - "The clinicopathological and prognostic significance of human epidermal growth factor receptor 2 (HER2) status in surgically resected colorectal liver metastases (CRLM) remains uncertain. " 01/01/2021 - "Most BCs with cutaneous metastasis are human epidermal growth factor receptor 2 (HER2)-positive subtypes. "

Related Drugs and Biologics

1.	Trastuzumab (Herceptin)
2.	Hormones (Hormone)
3.	pertuzumab
4.	Monoclonal Antibodies
5.	Estrogen Receptors
6.	Lapatinib (GW572016)
7.	Ado-Trastuzumab Emtansine
8.	Docetaxel (Taxotere)
9.	Progesterone Receptors (Progesterone Receptor)
10.	ErbB Receptors (EGF Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Neoadjuvant Therapy
4.	Adjuvant Chemotherapy
5.	Immunotherapy